Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a bispecific antibody newly licensed by Pfizer.

Clinical trial results reveal an experimental treatment by Pfizer and Arvinas that delays breast cancer progression by over ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

As regards Pfizer, oncology sales comprise around 25% of ... But which one is a better investment today? Let’s take a closer look at their fundamentals, growth prospects and challenges to ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...